Medical Microinstruments (MMI) raised $125 million in a Series D round to expand its Symani Surgical System and to pursue new microsurgery applications. The company also outlined an experimental initiative exploring a possible approach to treating Alzheimer’s disease, reflecting a push to translate core robotic capabilities into therapeutic research. The financing supports scaling of the robotic platform’s adoption while funding exploratory work aimed at widening use cases. MMI’s strategy highlights how surgical automation is increasingly being positioned as a research enabler, not just a device offering. For the biotech sector, the round underscores continued investment flow into cross-functional healthcare technologies—where automation and data-driven workflows may help de-risk future clinical development in areas with unmet need.